Chemopreventive Effects of an HDAC2-Selective Inhibitor on Rat Colon Carcinogenesis and APCmin/+ Mouse Intestinal Tumorigenesis

被引:11
作者
Ravillah, Durgadevi [1 ]
Mohammed, Altaf [1 ]
Qian, Li [1 ]
Brewer, Misty [1 ]
Zhang, Yuting [1 ]
Biddick, Laura [1 ]
Steele, Vernon E. [2 ]
Rao, Chinthalapally V. [1 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Ctr Canc Prevent & Drug Dev, Hematol Oncol Sect,Dept Med,PCS Oklahoma Canc Ctr, Oklahoma City, OK 73104 USA
[2] NCI, Canc Prevent Div, Chemoprevent Agent Dev Res Grp, NIH, Bethesda, MD 20892 USA
关键词
HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; CELL-CYCLE; PHASE-I; CHROMATIN-STRUCTURE; MOLECULAR-ORIGINS; COLORECTAL-CANCER; HDAC2; EXPRESSION; APC; APOPTOSIS;
D O I
10.1124/jpet.113.208645
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Epigenetic modulators, particularly histone deacetylases (HDACs), are valid targets for cancer prevention and therapy. Recent studies report that HDAC2 overexpression is associated with colon tumor progression and is a potential target for colon cancer prevention. This study tested chemopreventive and dose-response effects of Ohio State University HDAC42 (OSU-HDAC42), a selective HDAC2 inhibitor, using a rat colon carcinogenesis model to assess aberrant crypt foci inhibition and a familial adenomatous polyposis model to assess intestinal tumor inhibition. Colonic aberrant crypt foci were induced by azoxymethane (AOM) (15 mg/kg body weight, once-weekly subcutaneous injections at 8 and 9 weeks age). One week after AOM treatment, groups of rats were fed an AIN-76A diet containing 0, 75, 150, and 300 ppm OSU-HDAC42 for 8 weeks, and colonic aberrant crypt foci were evaluated. To assess the inhibitory effect of OSU-HDAC42 on small-intestinal polyps and colon tumor growth, 6-week-old male C57Bl/6J-APC(min/+)mice were fed an AIN-76A diet containing 150 ppm OSU-HADC42 or 300 ppm pan-HDAC inhibitor suberoylanilide hydroxyamic acid (SAHA) for 80 days. Our results demonstrate that dietary OSU-HDAC42 produced dose-dependent inhibition of AOM-induced colonic aberrant crypt foci formation (13-50%; P, 0.01 to, 0.0001) and reduced multiple crypts with >= 4 crypts per focus (25-57%; P, 0.01 to, 0.0001) in F344 rats. Our findings show that 150 ppm OSU-HDAC42 significantly inhibited small-intestinal polyps (. 46%; P, 0.001), with polyp size measuring.1 mm (P, 0.001), and colon tumors (. 26%) in APCmin/1mice, whereas 300 ppm SAHA showed nonsignificant inhibition. Mice fed 150 ppm OSU-HDAC42 had significantly decreased HDAC2, proliferating cell nuclear antigen, B cell lymphoma 2, cyclin-dependent kinase 2, and cell division cycle homolog 25C expression levels and increased p53 expression levels. These observations demonstrate the chemopreventive efficacy of OSU-HDAC42 against chemically induced and polyposis models of intestinal tumorigenesis.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 49 条
[11]   PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs [J].
He, TC ;
Chan, TA ;
Vogelstein, B ;
Kinzler, KW .
CELL, 1999, 99 (03) :335-345
[12]   Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F [J].
Hershko, T ;
Chaussepied, M ;
Oren, M ;
Ginsberg, D .
CELL DEATH AND DIFFERENTIATION, 2005, 12 (04) :377-383
[13]   Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 [J].
Huang, BH ;
Laban, M ;
Leung, CHW ;
Lee, L ;
Lee, CK ;
Salto-Tellez, M ;
Raju, GC ;
Hooi, SC .
CELL DEATH AND DIFFERENTIATION, 2005, 12 (04) :395-404
[14]   Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells [J].
Jiang, M ;
Milner, J .
GENES & DEVELOPMENT, 2003, 17 (07) :832-837
[15]  
Jin Ke Long, 2008, J Gynecol Oncol, V19, P185, DOI 10.3802/jgo.2008.19.3.185
[16]   Histone deacetylases specifically down-regulate p53-dependent gene activation [J].
Juan, LJ ;
Shia, WJ ;
Chen, MH ;
Yang, WM ;
Seto, E ;
Lin, YS ;
Wu, CW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (27) :20436-20443
[17]   HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins [J].
Jung, Kwang Hwa ;
Noh, Ji Heon ;
Kim, Jeong Kyu ;
Eun, Jung Woo ;
Bae, Hyun Jin ;
Xie, Hong Jian ;
Chang, Young Gyoon ;
Kim, Min Gyu ;
Park, Hanna ;
Lee, Jung Young ;
Nam, Suk Woo .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (06) :2167-2177
[18]   Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer [J].
Kelly, WK ;
O'Connor, OA ;
Krug, LM ;
Chiao, JH ;
Heaney, M ;
Curley, T ;
MacGregore-Cortelli, B ;
Tong, W ;
Secrist, JP ;
Schwartz, L ;
Richardson, S ;
Chu, E ;
Olgac, S ;
Marks, PA ;
Scher, H ;
Richon, VM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3923-3931
[19]  
Kelly WK, 2003, CLIN CANCER RES, V9, P3578
[20]   Lessons from hereditary colorectal cancer [J].
Kinzler, KW ;
Vogelstein, B .
CELL, 1996, 87 (02) :159-170